WALTHAM, Mass.–– PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the availability of the HER2Sense™ preclinical imaging agent, to support breast cancer

discovery research into personalized medicine. The HER2Sense agent is the first fluorescent, discovery research imaging

agent to be based on a commercialized therapeutic antibody.

The HER2Sense agent is an antibody-based optical probe for research applications that offers high therapeutic relevance

because it is based on Trastuzumab, a well-characterized and validated commercially-available therapeutic antibody used to

detect the HER2/Neu receptor for treating forms of cancer. The HER2Sense agent incorporates PerkinElmer’s proprietary

VivoTag™ fluorescent dye, which is specifically optimized for use in living systems and Trastuzumab is being supplied by

Roche Custom Biotech.

The therapeutic relevance of the HER2Sense agent offers significant value in helping researchers understand the mechanisms

of disease, especially as they relate to personalized medicine. For example, current clinical consensus is that the most effective approach in treating breast cancer is through personalized diagnostic methods. Additionally, clinician opinion has grown around the observation that targeting and modulating HER2 functionality appears to have shown significant promise as a therapeutic tool. As Trastuzumab has been well-characterized in clinical settings, translating this knowledge to preclinical research is believed to be an important step in developing a more complete understanding of the disease model.

According to Peter Schramm, Vice President Custom Biotech US at Roche Applied Science, “There is a clear need for the data

generated in animal research to be more relevant to clinical diagnosis, treatment, and even prognosis. The specificity of the Trastuzumab antibody, combined with the detection characteristics of PerkinElmer’s VivoTag dye, labeled with a high degree of consistency by Roche, will provide an important tool for discovery research applications. We believe that providing researchers the same antibody utilized in the clinical market will provide a valuable continuum between research data and clinical efficacy. We are excited to be collaborating with PerkinElmer to provide products designed to contribute to the advancement of cancer research.”

Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, “We are pleased to announce the launch of the

HER2Sense imaging agent to support research into breast and other types of cancer. As the HER2Sense agent is based on

Trastuzumab, an existing therapeutic antibody whose action and effects are well known and documented, it is anticipated that

the HER2Sense agent will provide researchers with strong analogs between discovery research and clinical research

outcomes. This imaging agent has the potential to provide oncology researchers with revolutionary new data and insights that

could influence the development of innovative methods for detecting a range of cancers, and to better guide treatment

options.”

Because Trastuzumab specifically detects the HER2/Neu receptor, the HER2Sense agent can also be used to interrogate the

status of the HER2/Neu receptor in other non-breast cancer models in living animal systems. The high sensitivity of the

HER2Sense agent has been shown to avoid the systemic immune response found in other antibody-based imaging agents

used in discovery research.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company

reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150

countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at

www.perkinelmer.com.